US pharmaceutical giant Merck announced on Friday the results of an internal study of its antiviral COVID-19 treatment pills. It said the results showed hospitalizations and deaths were reduced by half when taken by people recently infected with COVID-19, although academic peer review is not yet completed.
The company will soon ask health officials in the US and around the world to authorize the use of the drug, called molnupiravir. It would be the first antiviral pill to treat COVID-19 effectively, a potential turning point in the pandemic.
Read more at:
Merck says antiviral COVID-19 pill halves death and hospitalizations | News | DW | 01.10.2021
